Enveric Biosciences Unveils Library of Preclinical Compounds Across Multiple Distinct Molecule Classes Targeting Mental Health Disorders
Retrieved on:
Mercoledì, Febbraio 21, 2024
Biotechnology, Mental Health, Health, Pharmaceutical, Clinical Trials, Therapy, Addiction, Paroxetine, Anxiety, DMT, Mental health, SP, Imipramine, Artificial intelligence, Tri, Serotonin, BPP, Sleep, MT1, HTR, Aripiprazole, Fenfluramine, MDMA, Trazodone, Human, Mammal, Patient, Hallucination, Melatonin, DSM-IV codes, Plasma, ADHD, Literature, Research, Nefazodone, Mouse, Depression, Pharmaceutical industry
“As a result, Enveric now possesses what we believe to be one of the most diverse portfolios of potential drug molecules for the treatment of key, underserved mental health and neurological disorders.
Key Points:
- “As a result, Enveric now possesses what we believe to be one of the most diverse portfolios of potential drug molecules for the treatment of key, underserved mental health and neurological disorders.
- Enveric SNDRI compounds also demonstrate distinct additional serotonin receptor binding profiles that bear similarities to those of the antidepressant Nefazodone and the anxiolytic Buspirone.
- Enveric NSRI compounds show strong binding to SERT, as well as to the 5-HT1A receptor, known to be a therapeutically valuable target.
- For more information about Enveric’s novel preclinical compounds spanning multiple, distinct classes of molecules, please visit: https://www.enveric.com/psybrary .